» Articles » PMID: 34607050

Osteoclast-mediated Bone Loss Observed in a COVID-19 Mouse Model

Abstract

The consequences of SARS-CoV-2 infection on the musculoskeletal system represent a dangerous knowledge gap. Aging patients are at added risk for SARS-CoV-2 infection; therefore, a greater understanding of the resulting musculoskeletal sequelae of SARS-CoV-2 infection may help guide clinical strategies. This study examined fundamental bone parameters among mice treated with escalating viral loads. Male C57BL/6J (WT, n = 17) and B6.Cg-Tg(K18-ACE2)2Prlmn/J mice (K18-hACE2 transgenic mice, n = 21) expressing human ACE2 (TG) were divided into eight groups (n = 4-6/group) and subjected to intranasal dosing of 0, 1 × 10, 1 × 10, and 1 × 10 PFU (plaque forming units) of human SARS-CoV-2. Animal health was assessed daily by veterinary staff using established and validated scoring criteria (activity, posture, body condition scores and body weight). We report here that mock and WT infected mice were healthy and completed the study, surviving until 12-14 days post infection (dpi). In contrast, the TG mice infected with 1 × 10 PFU all experienced severe health declines that necessitated early euthanasia (6-7 dpi). For TG mice infected with 1 × 10 PFU, 2 mice were also euthanized after 7 dpi, while 3 mice showed signs of moderate disease at day 6 dpi, but recovered fully by day 11 dpi. Four of the 5 TG mice that were infected with 1 × 10 PFU remained healthy throughout the study. This suggests that our study mimics what is seen during human disease, where some patients develop severe disease resulting in death, while others have moderate to severe disease but recover, and others are asymptomatic. At necropsy, femurs were extracted and analyzed by μCT. No difference was found in μCT determined bone parameters among the WT groups. There was, however, a significant 24.4% decrease in trabecular bone volume fraction (p = 0.0009), 19.0% decrease in trabecular number (p = 0.004), 6.2% decrease in trabecular thickness (p = 0.04), and a 9.8% increase in trabecular separation (p = 0.04) among surviving TG mice receiving any viral load compared to non-infected controls. No differences in cortical bone parameters were detected. TRAP staining revealed surviving infected mice had a significant 64% increase in osteoclast number, a 27% increase in osteoclast surface, and a 38% increase in osteoclasts per bone surface. While more studies are needed to investigate the long-term consequences of SARS-CoV-2 infection on skeletal health, this study demonstrates a significant reduction in several bone parameters and corresponding robust increases in osteoclast number observed within 2 weeks post-infection in surviving asymptomatic and moderately affected mice.

Citing Articles

The antidiabetic effect of safflower yellow by regulating the GOAT/ghrelin/GHS-R1a/cAMP/TRPM2 pathway.

Ma Y, Zhang H, Yan Q, Wang P, Guo W, Yu L Sci Rep. 2025; 15(1):5037.

PMID: 39934157 PMC: 11814266. DOI: 10.1038/s41598-025-87201-6.


Incidence and Outcomes of Vertebral Compression Fracture Among Patients Infected with COVID-19.

Zhang H, Balmaceno-Criss M, Fruge A, Massey P, Daniels A, Zhang A J Clin Med. 2025; 13(24.

PMID: 39768754 PMC: 11680045. DOI: 10.3390/jcm13247830.


SARS-CoV-2 ORF8 drives osteoclastogenesis in preexisting immune-mediated inflammatory diseases.

Melano I, Azamor T, Caetano C, Meyer N, Onwubueke C, Visperas A JCI Insight. 2024; 9(24).

PMID: 39704167 PMC: 11665583. DOI: 10.1172/jci.insight.178820.


The impact of osteosarcopenia and its parameters on mortality of COVID-19 in-hospitalized older patients: the findings of BEH (Bushehr elderly health) program.

Shafiee G, Marzban M, Abbaspour F, Darabi A, Zargar Balajam N, Farhadi A J Diabetes Metab Disord. 2024; 23(2):1919-1928.

PMID: 39610491 PMC: 11599644. DOI: 10.1007/s40200-024-01443-1.


Bone Mineral Density, Bone Biomarkers, and Joints in Acute, Post, and Long COVID-19: A Systematic Review.

Alghamdi F, Mokbel K, Meertens R, Obotiba A, Alharbi M, Knapp K Viruses. 2024; 16(11).

PMID: 39599809 PMC: 11599111. DOI: 10.3390/v16111694.


References
1.
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

2.
Olfert E, Godson D . Humane endpoints for infectious disease animal models. ILAR J. 2001; 41(2):99-104. DOI: 10.1093/ilar.41.2.99. View

3.
Tao H, Ge G, Li W, Liang X, Wang H, Li N . Dysimmunity and inflammatory storm: Watch out for bone lesions in COVID-19 infection. Med Hypotheses. 2020; 145:110332. PMC: 7536122. DOI: 10.1016/j.mehy.2020.110332. View

4.
La Rosee F, Bremer H, Gehrke I, Kehr A, Hochhaus A, Birndt S . The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020; 34(7):1805-1815. PMC: 7282206. DOI: 10.1038/s41375-020-0891-0. View

5.
Bao L, Deng W, Huang B, Gao H, Liu J, Ren L . The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020; 583(7818):830-833. DOI: 10.1038/s41586-020-2312-y. View